Nor Azrina Norahmad1*, Lam Kok Wai2, Mohd Ridzuan Mohd Abd Razak3, and Zeti-Azura Mohamed-Hussein4, Ibrahim Jantan1
1. Institute of Systems Biology (INBIOSIS), Universiti Kebangsaan Malaysia, 43600 UKM Bangi, Selangor, Malaysia
2. Centre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia
3. Herbal Medicine Research Centre, Institute for Medical Research, National Institutes of Health, 40170 Shah Alam, Selangor, Malaysia
4. Department of Applied Physics, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, 43600 UKM Bangi, Selangor, Malaysia
*Corresponding author: Nor Azrina Norahmad.
ABSTRACT
INTRODUCTION: COVID-19 pathogenesis involves simultaneous viral replication and dysregulated host inflammatory response, often resulting in severe respiratory complications. Amid the ongoing search for effective therapeutics, natural compounds have attracted growing interest due to their broad-spectrum antiviral and anti-inflammatory activities.
OBJECTIVE(S): This study aimed to explore the dual inhibitory potential of selected natural compounds against SARS-CoV-2 replication and host inflammatory pathways using integrated in silico approaches.
MATERIALS & METHODS: A total of 65 natural immunomodulatory compounds were screened for their pharmacokinetic properties, including absorption, distribution, metabolism, excretion, and toxicity (ADMET). Molecular docking was performed to predict binding affinities toward key target proteins: SARS-CoV-2 main protease (3CLpro) and human cyclooxygenase-2 (hCOX2). Compounds demonstrating strong binding were subjected to 100 ns molecular dynamics (MD) simulations to evaluate the stability of protein–ligand complexes. Binding free energies (BFE) were calculated using the Molecular Mechanics/Generalised Born Surface Area (MM-GBSA) method.
RESULTS: Five compounds (lycorine, baicalein, butein, isoliquiritigenin, and corilagin) exhibited strong predicted binding affinities toward both 3CLpro and hCOX2. MD simulation analyses confirmed stable binding modes, consistent interaction profiles, and favourable conformational dynamics with both targets. MM-GBSA analysis further validated their strong binding potential. Against 3CLpro, the reference compound nirmatrelvir showed the strongest BFE (−28.79 kcal/mol). Among the natural candidates, butein demonstrated the most favourable binding (−23.31 kcal/mol), followed by isoliquiritigenin (−21.80 kcal/mol) and lycorine (−16.36 kcal/mol). For hCOX2, butein again exhibited the strongest BFE (−31.61 kcal/mol), surpassing the positive control rofecoxib (−30.44 kcal/mol), while isoliquiritigenin (−27.80 kcal/mol) and lycorine (−17.78 kcal/mol) also showed strong binding affinities. Butein and isoliquiritigenin show strong dual-target potential.
CONCLUSION: The favourable binding energies suggest the potential of selected natural compounds as dual-action inhibitors of SARS-CoV-2 3CLpro and hCOX2, offering molecular-level insights into their role in suppressing both viral replication and inflammation.
KEYWORDS: 3CLpro Inhibition, S-protein Inhibition, Cyclooxygenase-2, Molecular Docking and Dynamics, Natural Compounds


